Brand dynamics
Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health
Shenzhen ranks among 43 companies! Health-Yuan is selected as one of the top 500 innovative companies in China's A-share market.
Published Time：
2020-08-07
Core Tip: According to the "2020 China Listed Companies Innovation Index Report" jointly released by Zhejiang University School of Management and Shenzhen Press Group's Deep New Communication Think Tank on August 6, Beijing, Shenzhen, Shanghai, Hangzhou, Guangzhou, and Nanjing ranked among the top six cities in terms of innovation capabilities.
On August 6, the "2020 China Listed Companies Innovation Index Report" jointly released by Zhejiang University School of Management and Shenzhen Press Group's Deep New Communication Think Tank showed that Beijing, Shenzhen, Shanghai, Hangzhou, Guangzhou, and Nanjing ranked among the top six cities in innovation capabilities. With its outstanding performance in R&D and innovation, Joincare Pharmaceutical Group Industry Co., Ltd. (hereinafter referred to as "Health Yuan Group") was successfully selected among the top 500 companies along with 43 other excellent Shenzhen enterprises, including ZTE, Industrial Fulian, and BYD.
Since 2015, Zhejiang University School of Management has used China's A-share listed companies as samples to compile and publish the "China Listed Companies Innovation Index Report" annually. In terms of index construction, it strives to overcome the problems of most existing innovation index evaluations that heavily rely on expert subjective judgment in the selection of evaluation indicators and the generation of evaluation weights, paying more attention to R&D investment and patents and other technical factors while neglecting non-technical innovation (such as business model innovation), and paying more attention to the "quantity" of innovation output (the scale of innovation investment) while neglecting the "quality" of innovation output (such as the efficiency of innovation resource utilization).
According to the introduction, the report selects 2146 A-share companies as the evaluation objects, based on a two-dimensional innovation index evaluation system composed of innovation potential and innovation efficiency, it releases the 2019 China A-share listed companies innovation index top 500, innovation potential top 200, and innovation efficiency top 200, and conducts in-depth analysis of the regional distribution, industry, and investment portfolio returns of the top 500 innovation index companies, in order to help people understand the characteristics of innovative companies, regional distribution, and the correlation between company innovation index and investment returns. It is worth mentioning that the portfolio return rate constructed by the top 50 innovation index and innovation efficiency scores are 43.11% and 43.58% respectively, exceeding the same period return rates of the Shanghai Composite Index, Shanghai 50, Shanghai 180, SSE 300, Shenzhen 100, and Shenzhen 300, showing its investment reference value.
Public information shows that Health Yuan Group has diversified and multi-layered R&D institutions, with strong R&D capabilities and international R&D concepts in the fields of chemical and Chinese medicine preparations, biological drugs, diagnostic reagents, and health foods. It has a clear product R&D pipeline around product lines in areas such as antimicrobials, anti-tumor, gonadotropins, digestion, nerves, and respiration. By actively introducing senior domestic and foreign experts and innovative talents, increasing R&D investment, and establishing overseas strategic alliances, the company's R&D competitiveness has been further enhanced.
Health Yuan Group has always focused on "talent, platform, system, and culture," taking innovative development as its main theme, attaching importance to R&D innovation, and deeply deploying inhalation preparations. It has overcome technical barriers and obtained registration approvals for inhalation compound ipratropium bromide solution (Shutanlin®) and salbutamol hydrochloride nebulization solution (Lishutong®) in 2019. In July this year, the company's new nebulization product—0.5mg inhaled budesonide suspension (Wushu®)—was launched, becoming the first domestically produced small-specification budesonide to pass consistency evaluation! These achievements have milestone significance in the R&D of domestic inhalation preparation generic drugs, providing high-quality and safe drug options for more than 100 million asthma and chronic obstructive pulmonary disease patients in China.
Under the current national policy of continuously promoting the "Healthy China" strategy and the Guangdong-Hong Kong-Macao Greater Bay Area's efforts in the big health industry, Health Yuan Group has ushered in new development opportunities. In the future, Health Yuan Group will continue to take the revitalization of the national pharmaceutical industry as its mission, aiming to become one of China's leading pharmaceutical companies. It will adhere to innovation-driven development, continuously optimize and strengthen its sustainable development path, improve the group's core competitiveness, and contribute to building a healthy China and realizing the Chinese Dream of the great rejuvenation of the Chinese nation.
Source: China Industrial Development Research Network
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.